Program
Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506
Its studies are mostly in Carcinoma, Renal Cell, led by Bristol-Myers Squibb.
Furthest: phase 1, since Sep 25, 20251 company-led study, 1 open or runningNext primary completion: May 3, 2030 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 11 open or running | phase 1since Sep 25, 2025 | Sep 25, 2025 | May 3, 2030phase 1 · NCT07195682 |
- Named in Bristol-Myers Squibb’s own pipeline as
BMS-986506
, phase 1, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 25, 2025First study: phase 1 study in Carcinoma, Renal CellFirst studyNCT07195682 · 281 planned · United States, Canada, France and more
Ahead
- May 3, 2030Primary completion: phase 1 study in Carcinoma, Renal CellNCT07195682
TargetBeta
“A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential antineoplastic activity. Upon administration, cereblon E3 ubiquitin ligase modulating drug BMS-986506 specifically targets and binds to cereblon (CRBN), thereby affecting the ubiquit…”NCIt, read by Claude
Other programs on CRBN
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lenalidomiderule | Bristol-Myers Squibb | phase 4 | 109 |
| pomalidomiderule | Bristol-Myers Squibb | phase 4 | 51 |
| mezigdomide | Bristol-Myers Squibb | phase 3 | 12 |
| golcadomide | Bristol-Myers Squibb | phase 3 | 11 |
| HRS-3738 | Jiangsu HengRui Medicine | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07195682Carcinoma, Renal Cell · United States, Canada, France and more | 1 | Recruiting | May 3, 2030 | 281 |
How it is read
Names in the registry
- “BMS-986506”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.